SCHEMBL19970786

SCHEMBL19970786

O=C(c1ccc2[nH]c(C(c3ccccc3)c3ccccc3)nc2c1)N1CCN(Cc2cccc(OC(F)(F)F)c2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 1/20 0.48
LMNA P02545 3/20 0.48
KDM4E B2RXH2 3/20 0.48
ALDH1A1 P00352 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
GAA P10253 1/20 0.48
MGLL Q99685 5/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
MAPT P10636 1/20 0.47
RECQL P46063 1/20 0.47
MAPK14 Q16539 2/20 0.46
NPC1 O15118 1/20 0.46
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KCNK3 O14649 1/20 0.44
KCNK9 Q9NPC2 1/20 0.44
SIGMAR1 Q99720 1/20 0.43
OPRM1 P35372 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19970787 0.94 STAT3 (0.48) STAT3LMNAKDM4EALDH1A1SMN1; SMN2
SCHEMBL19970742 0.92 LSS (0.51) STAT3LMNAKDM4EALDH1A1SMN1; SMN2
SCHEMBL19970789 0.88 OPRM1 (0.47) KDM4EALDH1A1MGLLMEN1KMT2A
SCHEMBL19970750 0.86 MEN1 (0.53) STAT3LMNAKDM4EALDH1A1SMN1; SMN2
SCHEMBL19970743 0.85 LSS (0.51) STAT3LMNAKDM4EALDH1A1SMN1; SMN2
SCHEMBL19970880 0.84 SIGMAR1 (0.58) STAT3LMNAALDH1A1SMN1; SMN2MEN1
SCHEMBL19970790 0.83 RUNX1 (0.50) KDM4EALDH1A1MGLLMEN1KMT2A
SCHEMBL19970748 0.82 STAT3 (0.51) STAT3LMNAKDM4EALDH1A1SMN1; SMN2
SCHEMBL19970751 0.80 BCHE (0.55) STAT3LMNAKDM4EALDH1A1SMN1; SMN2
SCHEMBL19970864 0.80 STAT3 (0.51) STAT3LMNAKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11479571-B2 Benzimidazol derivatives for treating filovirus infection CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2022-10-25 US disclosed
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION UNIVERSITE D'ORLEANS (FR) 2021-09-23 US disclosed
EP-3296297-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION FIP1L1, ZC3HAV1, MAVS STAT3 2805/4885LMNA 614/4885KDM4E 1873/4885
US-11479571-B2 Benzimidazol derivatives for treating filovirus infection FIP1L1, ZC3HAV1, MAVS STAT3 2805/4885LMNA 614/4885KDM4E 1873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.